IL159033A0 - A pharmaceutical combination comprising either (s) -2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl)ethoxy] phenyl}-(s) -2- ethoxy propanoic acid and a biguanide drug - Google Patents

A pharmaceutical combination comprising either (s) -2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl)ethoxy] phenyl}-(s) -2- ethoxy propanoic acid and a biguanide drug

Info

Publication number
IL159033A0
IL159033A0 IL15903302A IL15903302A IL159033A0 IL 159033 A0 IL159033 A0 IL 159033A0 IL 15903302 A IL15903302 A IL 15903302A IL 15903302 A IL15903302 A IL 15903302A IL 159033 A0 IL159033 A0 IL 159033A0
Authority
IL
Israel
Prior art keywords
ethoxy
phenyl
propanoic acid
tert
pharmaceutical combination
Prior art date
Application number
IL15903302A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL159033A0 publication Critical patent/IL159033A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
IL15903302A 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s) -2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl)ethoxy] phenyl}-(s) -2- ethoxy propanoic acid and a biguanide drug IL159033A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101980A SE0101980D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination
PCT/SE2002/001038 WO2002096402A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a biguanide drug

Publications (1)

Publication Number Publication Date
IL159033A0 true IL159033A0 (en) 2004-05-12

Family

ID=20284362

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15903302A IL159033A0 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s) -2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl)ethoxy] phenyl}-(s) -2- ethoxy propanoic acid and a biguanide drug

Country Status (24)

Country Link
US (1) US20040152771A1 (cs)
EP (2) EP1666034A1 (cs)
JP (1) JP2004532864A (cs)
KR (1) KR20040008202A (cs)
CN (1) CN1535144A (cs)
AT (1) ATE336993T1 (cs)
BR (1) BR0210128A (cs)
CA (1) CA2448643A1 (cs)
CO (1) CO5540375A2 (cs)
CZ (1) CZ20033234A3 (cs)
DE (1) DE60214185T2 (cs)
EE (1) EE200300584A (cs)
ES (1) ES2269686T3 (cs)
HU (1) HUP0400946A3 (cs)
IL (1) IL159033A0 (cs)
IS (1) IS7058A (cs)
MX (1) MXPA03011005A (cs)
NO (1) NO20035237D0 (cs)
PL (1) PL367891A1 (cs)
RU (1) RU2003136154A (cs)
SE (1) SE0101980D0 (cs)
SK (1) SK14702003A3 (cs)
WO (1) WO2002096402A1 (cs)
ZA (1) ZA200309264B (cs)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201513857A (zh) * 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6552055B2 (en) * 1996-12-11 2003-04-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
PT1145717E (pt) * 2000-04-13 2004-08-31 Pfizer Prod Inc Efeito sinergistico de gliburide e milrinona

Also Published As

Publication number Publication date
EP1666034A1 (en) 2006-06-07
EE200300584A (et) 2004-02-16
DE60214185T2 (de) 2007-07-19
CA2448643A1 (en) 2002-12-05
PL367891A1 (en) 2005-03-07
RU2003136154A (ru) 2005-02-10
CO5540375A2 (es) 2005-07-29
ES2269686T3 (es) 2007-04-01
HK1062813A1 (en) 2004-11-26
DE60214185D1 (en) 2006-10-05
IS7058A (is) 2003-11-28
WO2002096402A1 (en) 2002-12-05
MXPA03011005A (es) 2004-02-27
EP1404309B1 (en) 2006-08-23
CN1535144A (zh) 2004-10-06
BR0210128A (pt) 2004-06-08
KR20040008202A (ko) 2004-01-28
ZA200309264B (en) 2005-02-28
EP1404309A1 (en) 2004-04-07
NO20035237D0 (no) 2003-11-25
US20040152771A1 (en) 2004-08-05
SE0101980D0 (sv) 2001-06-01
JP2004532864A (ja) 2004-10-28
HUP0400946A2 (hu) 2004-08-30
ATE336993T1 (de) 2006-09-15
CZ20033234A3 (cs) 2004-12-15
HUP0400946A3 (en) 2007-11-28
SK14702003A3 (sk) 2004-09-08

Similar Documents

Publication Publication Date Title
USD486333S1 (en) Tissue holder
EE200200284A (et) (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhappe peenestatud vorm
EE200200278A (et) (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhappe kristalne vorm
BR9910913A (pt) Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, e, processo para a profilaxia e/ou tratamento de condições clìnicas associadas com resistência a insulina
FR2826365B1 (fr) Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile
IL159033A0 (en) A pharmaceutical combination comprising either (s) -2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl)ethoxy] phenyl}-(s) -2- ethoxy propanoic acid and a biguanide drug
MXPA03011012A (es) Una combinacion farmaceutica que comprende ya sea acido (s)-2-etoi-3[4-(2-{4-metansulfonil oxifenil}etoxi)fenil) propanoico o acido 3-(4-[2-(4-terbutoxicarbonilaminofenil) etoxi] fenil}-(s)-2-etoxi propanoico e insulina.
MXPA03011010A (es) Una combinacion farmaceutica que comprende ya sea acido (s)-2-etoxi-3[4-(2-{4-metansulfonil oxifenil}etoxi)fenil] propanoico o acido 3-{4-[2-(4-terbutoxicarbonilaminofenil) etoxi] fenil}-(s)-2-etoxi propanoico y una sulfonilurea.
JP2006068522A (ja) おもちゃ組立ブロック
IS8224A (is) Amínsölt (-)-2-{[2-(4-hýdroxýfenýl)etýl]-þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}etýl)fenýl]própansýru og notkun þeirra í læknisfræði
HK1062527A (en) A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a sulonylurea
FR2838218B1 (fr) Affichage des imagettes d'un support photographique sur un terminal
CO5590908A2 (es) Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa
IS8234A (is) Kalíum- eða natríumsalt (-)-2-{[2-(4-hýdroxýfenýl)etýl]þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}fenýl]própansýru og notkun þeirra í læknisfræði
RS52014B (sr) Nova so benzoilgvanidina
USD458292S1 (en) Camera base
MXPA05013716A (es) Procedimiento para la preparacion de acido 2-([2-(4 -hidroxifenil) etil]tio)-3 -[4-(2-(2- [metilsulfonil) oxi]fenoxi) etil)fenil] -propanoico racemico.
BRPI0418226A (pt) preparação de cloridrato r-5-(2-(2-(2-etoxifenoxietilamino) propil-2-metoxibenzenossulfonamida de alta pureza quìmica
KR200203669Y1 (ko) 손톱깎이
JP2599292Y2 (ja) コンパクト容器
HK1087395A (en) Process for the preparation of racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio} -3-{4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid
KR950703579A (ko) 우레이도아세트아미드 유도체, 그들의 제조 및 상기를 함유하는 약제(urei-do-acetamide derivatives, preparation thereof and drugs con-taining same)
JPH11313738A (ja) すばやくコンパクトディスクのケースを交換しうる、2通りの壁面への固定法をもつ額縁
DE60142063D1 (de) (2s)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propion säureisopropylester, dessen herstellung und dessen verwendung
WO2003009732A1 (en) Keeping stand for lavatory and cosmetic goods